Arcturus Therapeutics Holdings Inc - Company Profile
Powered by 
All the sales intelligence you need on Arcturus Therapeutics Holdings Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Arcturus Therapeutics Holdings Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Arcturus Therapeutics Holdings Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Arcturus Therapeutics Holdings Inc (Arcturus Therapeutics) is a biotechnology company that develops messenger RNA (mRNA) medicines. It focuses on the discovery, development, and commercialization of medicines for the treatment of infectious diseases and rare diseases. The company's major products include a lipid nanoparticle (LNP) delivery system, LUNAR, and mRNA technology. Its pipeline product portfolio includes ARCT-810 (LUNAR-OTC), and ARCT-032 (LUNAR-CF). The company provides mRNA that is used as protein replacement therapy to treat diseases caused by a lack of protein or defective proteins, such as cystic fibrosis. LUNAR-CF is a grant program with the Cystic Fibrosis Foundation to treat cystic fibrosis using mRNA therapies. Arcturus Therapeutics Inc is headquartered in San Diego, California, the US.
Headquarters
United States of America
Address
10285 Science Center Drive, San Diego, California, 92121-1132
Website
www.arcturusrx.com
Telephone
1 858 9002660
No of Employees
106
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ARCT (NASD)
Revenue (2024)
$82.0M
-46.1%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
18.7%
(2024 vs 2023)
Market Cap*
$206.9M
Net Profit Margin (2024)
XYZ
-50.9%
(2024 vs 2023)
* As of and is in US$
Arcturus Therapeutics Holdings Inc premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| - | Service:- | - |
| Pipeline | Contract Drug Manufacturing Organization (CDMO) | STARR |
| ARCT-810 (LUNAR-OTC) | LUNAR | |
| XYZ | ||
| XYZ | ||
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Regulatory Approval | In February, the company received marketing approval for Kostaive, a self-amplifying mRNA COVID-19 vaccine from the European Commission. |
| 2024 | Regulatory Approval | In September, the company and CSL received approval from Japan’s Ministry of Health, Labor, and Welfare for their self-amplifying mRNA (sa-mRNA) vaccine, Kostaive (ARCT-154) in Japan to address the JN.1 strain of Covid-19. |
| 2024 | Contracts/Agreements | In May, the company partnered with Achilles Therapeutics plc to evaluate best-in-class, self-amplifying mRNA (sa-mRNA) personalized cancer vaccines targeting clonal neoantigens. |
Competitor Comparison
| Key Parameters | Arcturus Therapeutics Holdings Inc | Pfizer Inc | AstraZeneca Plc | Sanofi | Moderna Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United Kingdom | France | United States of America |
| City | San Diego | New York City | Cambridge | Paris | Cambridge |
| State/Province | California | New York | Cambridgeshire | Ile-de-France | Massachusetts |
| No. of Employees | 106 | 75,000 | 96,100 | 76,493 | 4,700 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Peter Farrell | Chairman | Executive Board | 2018 | 83 |
| Joseph E. Payne | President; Chief Executive Officer; Director | Executive Board | 2013 | 54 |
| Padmanabh Chivukula | Chief Operating Officer; Chief Scientific Officer | Senior Management | 2013 | 47 |
| Lance Kurata | Chief Legal Officer | Senior Management | 2020 | 56 |
| Alan H. Cohen | Chief Medical Officer | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer